all report title image
  • Published On : Aug 2022
  • Code : CMI84
  • Industry : Medical Devices
  • Pages : 110
  • Formats :

Deep brain stimulation (DBS) device, often described as brain pacemaker, aids in alleviating symptoms of Parkinson’s disease (PD). The device is implanted at one of the three U.S. Food and Drug Administration (FDA) approved brain sites to block the electrical signals from these sites to the brain. The three U.S. FDA approved targeted brain sites are ventrointermedialis (VIM) nucleus of the thalamus, subthalamic nucleus (STN), and globus pallidus pars interna (GPi). DBS surgery is performed on patients suffering from PD for at least four years and are on medications albeit with motor complications.

DBS is the most preferred option although, there are other surgical options such as Thalamotomy and Pallidotomy, as it does not involve tissue destruction and is a reversible surgical treatment.

Global deep brain stimulation device market size was valued at US$ 1,188.9 million in 2022 and is expected to witness a CAGR of 9.8% over the forecast period (2022 – 2030).

Figure 1. Global Deep Brain Stimulation Device Market Share (%), by Application, 2022

Deep Brain Stimulation Devices  | Coherent Market Insights

High prevalence of diseases such as Parkinson’s disease and epilepsy is expected to fuel the global deep brain stimulation devices market growth

Increasing prevalence of PD is expected to boost demand for DBS devices. For instance, according to the Parkinson’s disease Foundation, as of 2022, over 10 million people are suffering from Parkinson’s disease, worldwide. The findings published by the organization demonstrated that incidence rate of PD increases with age and only 4% of people were diagnosed with PD before the age of 50 years. According to the same source, in 2021, the incidence rate of PD in the U.S is as high as 60,000, annually.

Increasing prevalence of epilepsy is also expected to boost demand for DBS devices. For instance, according to the data published by the World Health Organization, on February 9, 2022, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low and middle-income countries like India, Kenya and Bangladesh.

Therefore, high prevalence of PD and epilepsy worldwide is expected to drive the global deep brain stimulation devices market growth over the forecast period.

CMI table icon

Deep Brain Stimulation Devices Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,188.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.8% 2030 Value Projection: US$ 2,508.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Application: Parkinson's Disease, Essential Tremor, Dystonia, Others
  • By End User: Hospital & Clinics, Ambulatory Surgical Centers, Others
Companies covered:

Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA.

Growth Drivers:
  • High prevalence of diseases such as Parkinson’s disease and epilepsy
  • Frequent approval and launch of novel devices
Restraints & Challenges:
  • The associated risks involved with deep brain stimulation procedures like misplacement of leads and bleeding in the brain

Figure 2. Global Deep Brain Stimulation Device Market Share (%), by Region, 2022

Deep Brain Stimulation Devices  | Coherent Market Insights

Frequent approval and launch of novel devices is expected to fuel the global deep brain stimulation devices market growth

Key players in the market are focused on approval and launch of novel DBS devices to expand their product portfolio, which is expected to boost the market growth. For instance, in January 2019, Boston Scientific Corporation launched two new DBS devices namely the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) systems.

Furthermore, key players in the market are focused on launching upgraded versions of their already approved DBS devices in the market. For instance, on May 24, 2022, OH – Great Lakes NeuroTechnologies (GLNT), diagnostic and therapy systems, announced that it has launched a multicenter research study to collect data to enhance its Kinesia motor assessment technology specifically for identifying when a patient with Parkinson’s disease (PD) is ready to consider an advanced therapy such as deep brain stimulation (DBS) or an implantable drug pump and recognize when a patient needs a therapy adjustment. The therapy is recommended when oral medication no longer provides sufficient relief of motor symptoms like rigidity, slowness of movement, fall and dizziness, freezing, muscle cramps and dystonia.

Global Deep Brain Stimulation Devices Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals. Manufacturers have found it difficult to serve their surgeon customers since some hospitals have restricted access to their facilities or changed access regulations. For instance, in December 2020, according to the report of National Center of Biotechnology Information, lockdown restriction measures were associated with subjective worsening of motor and psychiatric symptoms like significant tiredness, low energy or problems sleeping in Parkinson Disease and dystonic patients treated with DBS, and they may have exacerbated the burden of neurological disease and increased the chronic stress related to the DBS management.

Global Deep Brain Stimulation Devices Market: Key Developments

  • Increasing adoption of new technologies in the hospitals is expected to drive the growth of global deep brain stimulation devices market, according to press released by MGM Healthcare in February 2020, the MGM Healthcare, Tamil Nadu, performed first Deep Brain Stimulation (DBS) surgery for Obsessive Compulsive Neurosis or OCD, a mental illness.
  • Moreover, increasing number of prevalence of Parkinson’s Disease is expected to drive the growth of global deep brain stimulation devices market, according to a study report published by Parkinson’s Disease Society of the United Kingdom in 2022, it was estimated that the rate of prevalence in 2017, was 1-2 people in every 100,000 aged 20-29 and 4 or 5 people in every 100,000 aged 30-39. Prevalence increased with age with the prevalence for those aged 80-84 being 1,696 per 100,000 people which is equivalent to around 1.7% of this age-group in the U.K.
  • For instance, in January 2021, BrainsWay Ltd., a global advanced non-invasive treatment of brain disorders, announced an exclusive distribution agreement with Gaelan Medical Trade LLC, healthcare company with extensive distribution channels in the U.A.E. The agreement establishes a multiyear framework whereby BrainsWay will supply its patented, revolutionary Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is currently marketed in various markets for brain disorders including major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), to now be marketed and sold throughout the U.A.E.

Global Deep Brain Stimulation Devices Market Restraints

One of the key factors hampering the growth of global deep brain stimulation device market is the associated risks involved with deep brain stimulation procedures like misplacement of leads and bleeding in the brain. For instance, the fundamental power source and configurable component of DBS devices is the implanted pulse generator (IPG). The use of deep brain stimulation devices for Parkinson's disease is anticipated to be constrained by the danger of infections brought on by IPG. Therefore, healthcare stakeholders should raise knowledge about the use of tack-up sutures and lower profile devices, as well as antimicrobial impregnation and co-administration.

 Key Players

Key players operating in the global deep brain stimulation devices market include Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA.

Deep brain stimulation (DBS) surgery is performed as part of the treatment of various neural debilitating conditions such as Parkinson’s disease (PD), dementia, and Alzheimer’s disease. A patient fitted with a DBS device can get long-term relief from debilitating symptoms of PD. Although, some patients may require medications post-surgery, there is significant reduction in side-effects caused due to medications, owing to use of DBS devices. A DBS device is mainly placed in one of the three U.S. Food and Drug Administration (FDA) approved target sites in PD. Most commonly preferred target sites are the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN).

Market Dynamics

Approval and launch of novel and advanced DBS devices is expected to drive the global deep brain stimulation devices market growth over the forecast period. For instance, in January 2021, Medtronic plc, a U.S. based medical device company, announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson's disease based on a patient's clinical state.

DBS devices are widely used in the treatment and management of diseases such as epilepsy and PD. Therefore, high prevalence of these diseases worldwide is expected to drastically increase demand for its management devices, thereby driving the global deep brain stimulation devices market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) in June 2019, epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. Globally, around 50 million people suffer from epilepsy, making it one of the most common neurological diseases.

Key features of the study:                                          

  • This report provides an in-depth analysis of the global deep brain stimulation devices market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 – 2030), considering 2021, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global deep brain stimulation devices market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include, Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global deep brain stimulation devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global deep brain stimulation devices market

Detailed Segmentation:

  • Global Deep Brain Stimulation Device Market, By Application:
    • Parkinson's Disease
    • Essential Tremor
    • Dystonia
    • Others
  • Global Deep Brain Stimulation Device Market, By End User:
    • Hospital & Clinics
    • Ambulatory Surgical Centers
    • Others
  • Global Deep Brain Stimulation Device Market, By Region:
    • North America
      • By country
        • U.S.
        • Canada
    • Europe
      • By Country
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  •  Company Profiles
    • Boston Scientific Corporation.*
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Medtronic, Inc.
    • Jude Medical, Inc. (Abbott Laboratories)
    • Cyberonics, Inc.
    • Neuronetics
    • Aleva Neurotherapeutics SA.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global deep brain stimulation devices market is estimated to surpass US$ 2,508.5 Million by 2030.
Major players operating in the market include Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA.
Among Application, Parkinson Disease segment generated significant revenue in 2022, owing to increasing incidence of Parkinson Disease worldwide.
High prevalence of diseases such as Parkinson’s disease and epilepsy is expected to drive the market growth
The market is estimated to exhibit a CAGR of 9.8 % over the forecast period.
Among regions, North America is expected to witness significant growth over the forecast period, owing to frequent approval and launch of novel devices in market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo